The outcome of the so-called ‘FOURIER’ trial is extremely important for Amgen because the data will be used to lobby insurance companies to reimburse for Repatha. Amgen said Wednesday that its cholesterol-lowering drug Repatha achieved all efficacy endpoints in a closely watched clinical trial by reducing the risk of adverse cardiovascular events, including death.